Tonix Pharmaceuticals Holding Corp. (TNXP): Results of Operations and Financial Condition

Pfizer, Moderna, and others are developing Lyme disease treatments, including vaccines and drugs. Pfizer-Valneva's vaccine showed 73% efficacy in trials, with EU review underway. Tonix and Tarsus are working on preventive measures. Lyme cases have surged, with 476,000 annual diagnoses in the U.S. according to the CDC.

Tonix Pharmaceuticals (TNXP) announced it will present its TNX-801 vaccine platform at the World Vaccine Congress Europe 2026. TNX-801 is in preclinical development for mpox, smallpox, and other diseases, with a Phase 1 study expected in 2027. The company's shares rose 4.40% to $6.40.

Tonix Pharmaceuticals (TNXP) received a Paragraph IV notice from Dr. Reddy’s for a generic version of TONMYA. Dr. Reddy’s challenged four patents in an ANDA filing, triggering a 45-day window for Tonix to sue. Tonix plans to enforce its IP but cannot predict litigation outcomes or generic entry timing.

Tonix Pharmaceuticals Holding Corp. (TNXP) filed an SEC Form 8-K — Other Events. Exhibit 99.01 Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA ® New agreement, effective immediately, adds approximately 21 million Medicare lives (38% of approximately 55 million Medicare lives in the U.S.) Commercial and government payer

Tonix Pharmaceuticals' TNX-801, an investigational mpox vaccine, showed promise in preclinical studies, offering durable immunity and potential advantages over existing vaccines. According to Sina Bavari, PhD, the vaccine demonstrated robust immune responses and protection in animal models. Tonix aims to address unmet needs in infectious disease preparedness, with TNX-801 being part of its broader biodefense strategy. The company highlights the importance of next-generation vaccines in preventin

Tonix Pharmaceuticals (TNXP) reported Q2 2026 net product revenue of $13.5 million, including $11.0 million TONMYA net sales, up from $2.0 million a year earlier. TONMYA generated 12,592 prescriptions and expanded payer coverage to 136 million lives. Cash was $176.2 million at June 30, 2026. R&D rose to $19.4 million; net loss was $40.6 million.